Clinical Trials · NCT07613307
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 130
- Start date
- Jul 2026
- Locations
- 40 sites, 4 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1C (HbA1c)